Relmada Therapeutics, Inc. RLMD Accrued Research And Development Current
Accrued Research And Development Current at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept rlmd:AccruedResearchAndDevelopmentCurrent.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s accrued research and development current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s accrued research and development current?
- Relmada Therapeutics, Inc. (RLMD) reported accrued research and development current of $1.82M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s accrued research and development current changed year-over-year?
- Relmada Therapeutics, Inc.'s accrued research and development current decreased by 29.1% year-over-year, from $2.57M to $1.82M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s accrued research and development current?
- Over 2 years (2023 to 2025), Relmada Therapeutics, Inc.'s accrued research and development current has grown at a -14.2% compound annual growth rate (CAGR), from $5.39M to $3.97M.
- What does accrued research and development current mean?
- Liabilities recognized for research and development services that have been performed by third parties but for which payment has not yet been processed. This reflects the current operational intensity of the company's drug development programs. Tracking this helps investors understand the immediate cash requirements needed to settle existing R&D obligations.